Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
Braz. j. infect. dis
; 15(3): 253-261, May-June 2011. tab
Article
in English
| LILACS
| ID: lil-589958
Responsible library:
BR1.1
ABSTRACT
OBJECTIVES:
To describe laboratory abnormalities among HIV-infected women and their infants with standard and increased lopinavir/ritonavir (LPV/r) dosing during the third trimester of pregnancy.METHODS:
We evaluated data on pregnant women from NISDI cohorts (2002-2009) enrolled in Brazil, who received at least 28 days of LPV/r during the third pregnancy trimester and gave birth to singleton infants.RESULTS:
164 women received LPV/r standard dosing [(798/198 or 800/200 mg/day) (Group 1)] and 70 increased dosing [(> 800/200 mg/day) (Group 2)]. Group 1 was more likely to have advanced clinical disease and to use ARVs for treatment, and less likely to have CD4 counts > 500 cells/mm³. Mean plasma viral load was higher in Group 2. There were statistically significant, but not clinically meaningful, differences between groups in mean AST, ALT, cholesterol, and triglycerides. The proportion of women with Grade 3 or 4 adverse events was very low, with no statistically significant differences between groups in severe adverse events related to ALT, AST, total bilirubin, cholesterol, or triglycerides. There were statistically significant, but not clinically meaningful, differences between infant groups in ALT and creatinine. The proportion of infants with Grade 3 or 4 adverse events was very low, and there were no statistically significant differences in severe adverse events related to ALT, AST, BUN, or creatinine.CONCLUSION:
The proportions of women and infants with severe laboratory adverse events were very low. Increased LPV/r dosing during the third trimester of pregnancy appears to be safe for HIV-infected women and their infants.
Full text:
Available
Collection:
International databases
Database:
LILACS
Main subject:
Pregnancy Complications, Infectious
/
Pyrimidinones
/
HIV Infections
/
HIV Protease Inhibitors
/
Ritonavir
/
Anti-HIV Agents
Type of study:
Etiology study
/
Incidence study
/
Observational study
/
Risk factors
Limits:
Female
/
Humans
/
Male
/
Infant, Newborn
/
Pregnancy
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2011
Document type:
Article
/
Project document
Affiliation country:
Argentina
/
Brazil
/
United States
Institution/Affiliation country:
Hospital Femina/BR
/
Hospital de Agudos Dra. Cecilia Grierson/AR
/
Hospital dos Servidores do Estado/BR
/
Irmandade da Santa Casa de Misericórdia de Porto Alegre/BR
/
NIH/US
/
Universidade Federal de Minas Gerais/BR
/
Universidade de Caxias do Sul/BR
/
Universidade de São Paulo/BR
/
Westat/US